Of Interest
Cancer Disappears in All Rectal Cancer Patients on Experimental Drug
The study, published in The New England Journal of Medicine, found that 18 patients with rectal cancer who were given the drug dostarlimab every three weeks for six months became cancer-free, including the first patient who remains in remission two years out from the trial
Newsmax
